IL94612A - Preparation of 4-amino-hydroxybutylidene-1,1-bisphosphonic or its salts - Google Patents

Preparation of 4-amino-hydroxybutylidene-1,1-bisphosphonic or its salts

Info

Publication number: IL94612A
Authority: IL; Israel
Prior art keywords: amino; acid; hydroxybutylidene; reaction; salts
Prior art date: 1989-06-09

Application number

IL9461290A

Other languages

English (en)

Hebrew (he)

Other versions

IL94612A0 (en

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-09

Filing date

1990-06-04

Publication date

1995-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23431886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL94612(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-06-04 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1991-04-15 Publication of IL94612A0 publication Critical patent/IL94612A0/xx

1995-03-30 Publication of IL94612A publication Critical patent/IL94612A/en

Links

239000002253 acid Substances 0.000 title claims abstract description 27
150000003839 salts Chemical class 0.000 title claims abstract description 12
238000002360 preparation method Methods 0.000 title claims abstract description 7
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims abstract description 14
229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 8
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 7
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims abstract description 4
229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims abstract description 3
238000006243 chemical reaction Methods 0.000 claims description 19
PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 claims description 6
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 abstract description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000000243 solution Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000007795 chemical reaction product Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
229910001868 water Inorganic materials 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000003085 diluting agent Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
238000003556 assay Methods 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000004448 titration Methods 0.000 description 2
-1 4-amino-l-hydroxybutylidene Chemical group 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000007605 air drying Methods 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000003518 caustics Substances 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
238000009838 combustion analysis Methods 0.000 description 1
238000003926 complexometric titration Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000007706 flame test Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
238000005580 one pot reaction Methods 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000005954 phosphonylation reaction Methods 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
229950011008 tetrachloroethylene Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Seasonings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

IL9461290A 1989-06-09 1990-06-04 Preparation of 4-amino-hydroxybutylidene-1,1-bisphosphonic or its salts IL94612A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/363,820 US4922007A (en)	1989-06-09	1989-06-09	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof

Publications (2)

Publication Number	Publication Date
IL94612A0 IL94612A0 (en)	1991-04-15
IL94612A true IL94612A (en)	1995-03-30

Family

ID=23431886

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9461290A IL94612A (en)	1989-06-09	1990-06-04	Preparation of 4-amino-hydroxybutylidene-1,1-bisphosphonic or its salts

Country Status (23)

Country	Link
US (1)	US4922007A (fr)
EP (1)	EP0402152B1 (fr)
JP (2)	JPH0662651B2 (fr)
KR (1)	KR0137455B1 (fr)
AT (1)	ATE129713T1 (fr)
AU (1)	AU625704C (fr)
CA (1)	CA2018477C (fr)
CH (1)	CH0402152H1 (fr)
CY (1)	CY1894A (fr)
DE (1)	DE69023280T2 (fr)
DK (1)	DK0402152T3 (fr)
ES (1)	ES2080116T3 (fr)
FI (1)	FI93219C (fr)
GR (1)	GR3018379T3 (fr)
HK (1)	HK69596A (fr)
HU (1)	HU211908A9 (fr)
IE (1)	IE69564B1 (fr)
IL (1)	IL94612A (fr)
LV (1)	LV11472B (fr)
NO (2)	NO177997C (fr)
NZ (1)	NZ233972A (fr)
PT (1)	PT94306B (fr)
ZA (1)	ZA904446B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5356887A (en) *	1990-01-31	1994-10-18	Merck & Co., Inc.	Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) *	1990-06-20	1991-05-28	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) *	1990-09-18	1992-10-27	Merck & Co., Inc.	Process for preparing an antihypercalcemic agent
US5039819A (en) *	1990-09-18	1991-08-13	Merck & Co., Inc.	Diphosphonate intermediate for preparing an antihypercalcemic agent
US5753634A (en) *	1992-05-29	1998-05-19	The Procter & Gamble Company	Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism
WO1993024496A1 (fr) *	1992-05-29	1993-12-09	Procter & Gamble Pharmaceuticals, Inc.	Composes de phosphonate contenant du soufre, et destines au traitement du metabolisme anormal du calcium et du phosphate
SG47603A1 (en) *	1992-05-29	1998-04-17	Procter & Gamble Pharma	Thio-substitute nitrogen containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism
US5763611A (en) *	1992-05-29	1998-06-09	The Procter & Gamble Company	Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5391743A (en) *	1992-05-29	1995-02-21	Procter & Gamble Pharmaceuticals, Inc.	Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
EP0646119B1 (fr) *	1992-05-29	1998-07-15	PROCTER & GAMBLE PHARMACEUTICALS, INC.	Composes quaternaires de phosphonate contenant de l'azote et servant a traiter le metabolisme anormal du calcium et du phosphate ainsi que le tartre et la plaque dentaire
FR2694558B1 (fr) *	1992-08-05	1994-10-28	Sanofi Elf	Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
US6406714B1 (en)	1992-12-02	2002-06-18	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids
US6399592B1 (en)	1992-12-23	2002-06-04	Merck & Co., Inc.	Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
FR2703590B1 (fr) *	1993-04-05	1995-06-30	Sanofi Elf	Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
TW257765B (fr) *	1993-08-25	1995-09-21	Merck & Co Inc
US5510517A (en) *	1993-08-25	1996-04-23	Merck & Co., Inc.	Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5854227A (en) *	1994-03-04	1998-12-29	Hartmann; John F.	Therapeutic derivatives of diphosphonates
US20010007863A1 (en) *	1998-06-18	2001-07-12	Merck & Co., Inc.	Wet granulation formulation for bisphosphonic acids
US5462932A (en) *	1994-05-17	1995-10-31	Merck & Co., Inc.	Oral liquid alendronate formulations
US5449819A (en) *	1994-06-06	1995-09-12	Merck & Co., Inc.	Process for removing waste pox, alendronate and its by products
US5589691A (en) *	1994-06-06	1996-12-31	Merck & Co., Inc.	Process for recovery and recycle of methanesulfonic acid and phosphorous acid
US5780455A (en) *	1994-08-24	1998-07-14	Merck & Co., Inc.	Intravenous alendronate formulations
KR19980702210A (ko) *	1995-02-17	1998-07-15	폴락 돈나 엘	비척추골 골절의 위험률을 감소시키는 방법
CA2219354A1 (fr) *	1995-05-12	1996-11-14	Merck & Co., Inc.	Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
AU5886096A (en) *	1995-06-06	1996-12-24	Merck & Co., Inc.	Anhydrous alendronate monosodium salt formulations
JPH11511041A (ja)	1995-06-06	1999-09-28	メルクエンドカンパニーインコーポレーテッド	整形外科的埋め込み装置の無菌性動揺を防止するビスホスホネートセメント組成物
AU6148396A (en) *	1995-06-06	1996-12-24	Merck & Co., Inc.	Disodium alendronate formulations
CZ116999A3 (cs) *	1996-10-04	1999-09-15	Merck And Co., Inc.	Vodný tekutý farmaceutický prostředek
JP2824453B2 (ja) *	1996-10-15	1998-11-11	株式会社ワカ製作所	コネクター
CA2197267C (fr) *	1997-02-11	2000-02-08	Yong Tao	Procede pour la preparation de l'acide 4-amino-1-hydroxybutylidene-1,1-bisphosphonique ou de ses sels
IL122009A0 (en) *	1997-10-21	1998-03-10	Unipharm Ltd	Salt of a bisphosphonic acid derivative
WO1999067809A1 (fr)	1998-06-24	1999-12-29	Merck & Co., Inc.	Compositions et procedes inhibant la resorption osseuse
US20030078211A1 (en) *	1998-06-24	2003-04-24	Merck & Co., Inc.	Compositions and methods for inhibiting bone resorption
US6008207A (en) *	1998-08-13	1999-12-28	Merck & Co., Inc.	Anhydrous alendronate monosodium salt formulations
SK2482001A3 (en)	1998-08-27	2002-01-07	Teva Pharma	Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1702924A3 (fr) *	1998-08-27	2007-07-18	Teva Pharmaceutical Industries Ltd	Formes de type hydrate du sel de sodium de l'alendronate, procédés de préparation et compositions pharmaceutiques
US6331533B1 (en)	1998-11-16	2001-12-18	Merck & Co., Inc.	Method for inhibiting dental resorptive lesions
US6160165A (en) *	1998-12-10	2000-12-12	Aesgen, Inc.	Method for preparation of disodium pamidronate
US6794536B1 (en)	1998-12-10	2004-09-21	Aesqen, Inc.	Method for preparation of disodium pamidronate
US6963008B2 (en) *	1999-07-19	2005-11-08	Teva Pharmaceutical Industries Ltd.	Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
ES2153794B1 (es) *	1999-08-06	2001-10-16	Medichem Sa	Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
AR021347A1 (es)	1999-10-20	2002-07-17	Cipla Ltd	Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001030788A1 (fr) *	1999-10-26	2001-05-03	A/S Gea Farmaceutisk Fabrik	Nouveaux sels d'acide 4- amino-1-hydroxy-butylidene-1,1-bisphosphonique, leur preparation et utilisation
US6476006B2 (en)	2000-06-23	2002-11-05	Teva Pharmaceutical Industries, Ltd.	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6558702B2 (en) *	2001-04-13	2003-05-06	Alkermes Controlled Therapeutics, Inc.	Method of modifying the release profile of sustained release compositions
US20060269602A1 (en) *	2001-04-13	2006-11-30	Dasch James R	Method of modifying the release profile of sustained release compositions
TR200101250A2 (tr) *	2001-05-10	2003-04-21	E�S Eczaciba�I �Zg�N K�Myasal �R�Nler Sanay� A.�.	4-amino-1-hidroksibutiliden-1,1-bifosfonik asit veya tuzlarının hazırlanmasına ilişkin proses
CA2372450A1 (fr) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Preparation injectable liquide de pamidronate disodique
GB2383042A (en) *	2001-10-18	2003-06-18	Cipla Ltd	Amorphous alendronate sodium
HUP0402267A3 (en) *	2001-12-21	2007-05-29	Procter & Gamble	Method for treatment of bone disorders
US20050070504A1 (en) *	2001-12-21	2005-03-31	The Procter & Gamble Co.	Risedronate compositions and their methods of use
JP4502641B2 (ja) *	2002-01-24	2010-07-14	ティルタンファーマリミテッド	抗癌組み合わせおよびその使用方法
ITMI20020146A1 (it) *	2002-01-29	2003-07-29	Lyogen Ltd	Alendronato monosodico amorfo e processo per la sua preparazione
ITMI20020908A1 (it) *	2002-04-29	2003-10-29	Chemi Spa	Processo di preparazione di sodio alendronato
KR20140021045A (ko) *	2002-05-10	2014-02-19	에프. 호프만-라 로슈 아게	골다공증 치료 및 예방용 비스포스폰산
AU2003233569A1 (en) *	2002-05-17	2003-12-02	Teva Pharmaceutical Industries Ltd.	Use of certain diluents for making bisphosphonic acids
EP1513523A1 (fr) *	2002-06-06	2005-03-16	Merck Frosst Canada & Co.	DERIVES D IMIDAZOLIDINE-2-ONE DISUBSTITUES EN 1,5 UTILES EN TANT QU AGONISTES DU RECEPTEUR EP sb 4 /sb DANS LE TRAITEME NT DE TROUBLES OCULAIRES ET DE MALADIES OSSEUSES
JP4485117B2 (ja) *	2002-06-27	2010-06-16	日東電工株式会社	保護剥離用フィルム
CA2495917A1 (fr) *	2002-08-28	2004-03-11	Merck Frosst Canada & Co.	Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
US20040138180A1 (en) *	2002-10-03	2004-07-15	Barr Laboratories, Inc.	Bisphosphonate composition and process for the preparation thereof
NZ536273A (en) *	2002-12-20	2007-08-31	Hoffmann La Roche	High dose ibandronate formulation
US20040206932A1 (en) *	2002-12-30	2004-10-21	Abuelyaman Ahmed S.	Compositions including polymerizable bisphosphonic acids and methods
HUP0300227A2 (hu) *	2003-01-28	2004-09-28	Richter Gedeon Vegyészeti Gyár Rt.	Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
US7449499B2 (en) *	2003-08-12	2008-11-11	3M Innovative Properties Company	Self-etching dental compositions and methods
JP4553899B2 (ja)	2003-08-21	2010-09-29	メルクフロストカナダリミテツド	カテプシンシステインプロテアーゼ阻害剤
ATE451380T1 (de) *	2003-08-21	2009-12-15	Sun Pharmaceuticals Ind Ltd	Verfahren zur herstellung von bisphosphonsäureverbindungen
KR20060058134A (ko) *	2003-09-19	2006-05-29	화이자 프로덕츠 인코포레이티드	2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
US20050113343A1 (en) *	2003-10-14	2005-05-26	Pliva - Research And Development Ltd.	Solid-state form of alendronate sodium and preparation thereof
US20050261250A1 (en) *	2004-05-19	2005-11-24	Merck & Co., Inc.,	Compositions and methods for inhibiting bone resorption
BRPI0511530A (pt)	2004-05-24	2008-01-02	Procter & Gamble	formas de dosagem de bisfosfonatos
UA87854C2 (en)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US8465284B2 (en) *	2004-07-08	2013-06-18	3M Innovative Properties Company	Dental methods, compositions, and kits including acid-sensitive dyes
US8722760B2 (en) *	2004-08-11	2014-05-13	3M Innovative Properties Company	Self-adhesive compositions including a plurality of acidic compounds
US7361761B2 (en) *	2004-09-28	2008-04-22	Orchid Chemicals & Pharmaceuticals Ltd.	Process for the preparation of bisphosphonic acid
US7214818B2 (en)	2004-10-29	2007-05-08	Hoffmann-La Roche Inc.	Method for synthesizing bisphosphonate
CN1304401C (zh) *	2004-12-28	2007-03-14	浙江工业大学	一种阿伦膦酸的制备方法
US8722734B2 (en)	2005-03-02	2014-05-13	Merck Sharp & Dohme Corp.	Composition for inhibition of cathepsin K
EP1865928A1 (fr) *	2005-03-17	2007-12-19	Elan Pharma International Limited	Compositions de biphosphanate nanoparticulaires
US7872144B2 (en) *	2005-06-13	2011-01-18	Jubilant Organosys Limited	Process for producing biphosphonic acids and forms thereof
AR054673A1 (es)	2005-07-28	2007-07-11	Gador Sa	Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
US8003820B2 (en) *	2005-10-20	2011-08-23	Dr. Reddy's Laboratories Limited	Process for preparing bisphosphonic acids
WO2007053564A2 (fr)	2005-10-31	2007-05-10	Cabot Corporation	Colorants modifiés et compositions d'encre pour impression par jet d'encre comprenant les colorants modifiés
EP1803727B1 (fr)	2005-12-27	2009-03-11	IPCA Laboratories Limited	Procédé amélioré de fabrication d'acides 4-amino-hydroxybutylidène-1,1-bisphosphonique et ses sels
WO2007083240A2 (fr)	2006-01-20	2007-07-26	Aurobindo Pharma Limited	Procede ameliore de preparation d’acides bisphosphoniques
CA2570949A1 (fr) *	2006-12-12	2008-06-12	Apotex Pharmachem Inc.	Solvate d'ibandronate sodique et de propyleneglycol et methodes de preparation connexes
CN101557791B (zh)	2006-12-13	2013-05-22	3M创新有限公司	使用具有酸性组分和可光漂白染料的牙科用组合物的方法
CN101679465B (zh)	2007-04-11	2013-08-21	霍夫曼-拉罗奇有限公司	伊班膦酸盐的制备方法
CA2689504A1 (fr) *	2007-06-19	2008-12-24	Albemarle Corporation	Procedes de fabrication d'acides bisphosphoniques
WO2009050731A2 (fr) *	2007-06-20	2009-04-23	Alkem Laboratories Ltd	Procédé inédit de préparation de l'acide risédronique
US20090170815A1 (en) *	2007-12-28	2009-07-02	Roxane Laboratories Incorporated.	Alendronate oral liquid formulations
CN101932306A (zh) *	2008-02-05	2010-12-29	阿特维斯集团公司	阿仑膦酸盐制剂、其制备方法和使用方法
WO2010003704A2 (fr) *	2008-07-11	2010-01-14	Synthon B.V.	Procédé de fabrication d'acides 1-hydroxyalkylidène-1,1-biphosphoniques
US20100130746A1 (en) *	2008-11-26	2010-05-27	Martin Kas	Process for Making Zoledronic Acid
US20120100206A1 (en)	2009-06-11	2012-04-26	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Targeted liposomes comprising n-containing bisphosphonates and uses thereof
WO2011023280A1 (fr)	2009-08-28	2011-03-03	Synthon B.V.	Procédé de fabrication d'acides 1-hydroxyalkylidène-1,1-biphosphoniques
JP5489126B2 (ja)	2009-09-30	2014-05-14	大日本印刷株式会社	インク組成物
CA2738045C (fr)	2010-05-28	2019-02-19	Simon Fraser University	Composes conjugues, leurs procedes de fabrication et leurs utilisations
WO2012007021A1 (fr)	2010-07-14	2012-01-19	Pharmathen S.A.	Procédé de synthèse du sel d'acide 3-(n-méthyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonique ou de ses dérivés
US9056991B2 (en)	2010-07-30	2015-06-16	Cabot Corporation	Polymeric pigment systems and methods
ES2716525T3 (es)	2010-12-06	2019-06-13	Effrx Pharmaceuticals Sa	Formulaciones de bisfosfonatos efervescentes estables con características de solubilización rápida
KR20140009266A (ko)	2010-12-27	2014-01-22	다이니폰 인사츠 가부시키가이샤	잉크젯 기록 방법
WO2012112363A1 (fr)	2011-02-14	2012-08-23	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine protéases, les cathepsines
US8814335B2 (en)	2011-03-29	2014-08-26	Dnp Fine Chemicals Co., Ltd.	Inkjet recording method and ink set for inkjet recording
EP2731591B1 (fr)	2011-07-13	2020-06-17	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Liposomes co-encapsulant un biphosphonate et un agent amphipathique
GB201200868D0 (en)	2012-01-19	2012-02-29	Depuy Int Ltd	Bone filler composition
JP5722860B2 (ja)	2012-10-11	2015-05-27	株式会社Ｄｎｐファインケミカル	水性インクジェット受理溶液、この受理溶液を含むインクセット及びこのインクセットを用いたインクジェット記録方法
WO2015051479A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine-protéases de type cathepsines
CA2923272A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Inhibiteurs de proteases a cysteine de type cathepsines
JP5779630B2 (ja)	2013-11-27	2015-09-16	株式会社Ｄｎｐファインケミカル	インクジェット記録用インク組成物、及びその製造方法、並びに、インクジェット記録方法
JP5676734B1 (ja)	2013-12-27	2015-02-25	株式会社Ｄｎｐファインケミカル	インクジェット記録用インク組成物、インクジェット記録方法、及び印刷物の製造方法
WO2015120580A1 (fr)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Inhibiteurs de protéases à cystéine de type cathépsines
PL407922A1 (pl)	2014-04-16	2015-10-26	Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością	Nowe bisfosfoniany i ich zastosowanie
US9650414B1 (en)	2014-05-30	2017-05-16	Simon Fraser University	Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
CN104072538A (zh) *	2014-07-10	2014-10-01	陕西汉江药业集团股份有限公司	一种双膦酸盐类药物的合成方法
US10400000B2 (en)	2015-06-12	2019-09-03	Simon Fraser University	Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
WO2020019108A1 (fr)	2018-07-23	2020-01-30	Guangzhou Othrotx Co., Ltd.	Conjugués médicamenteux à base de bisphosphonate
WO2023275715A1 (fr)	2021-06-30	2023-01-05	Pfizer Inc.	Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2534391C2 (de) *	1975-08-01	1983-01-13	Henkel KGaA, 4000 Düsseldorf	1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) *	1977-10-07	1985-05-02	Henkel KGaA, 4000 Düsseldorf	Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
DE2943498C2 (de) *	1979-10-27	1983-01-27	Henkel KGaA, 4000 Düsseldorf	Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) *	1980-04-28	1981-10-29	Henkel KGaA, 4000 Düsseldorf	Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) *	1980-10-16	1981-12-08	Vysoka Skola Chemicko-Technologicka	6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
IT1201087B (it) *	1982-04-15	1989-01-27	Gentili Ist Spa	Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) *	1984-08-06	1987-01-27	Ciba-Geigy Corporation	Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
IT1196315B (it) *	1984-10-29	1988-11-16	Gentili Ist Spa	Procedimento per la preparazione di acidi difosfonici

1989
- 1989-06-09 US US07/363,820 patent/US4922007A/en not_active Expired - Lifetime
1990
- 1990-06-04 IL IL9461290A patent/IL94612A/en active IP Right Review Request
- 1990-06-07 CA CA002018477A patent/CA2018477C/fr not_active Expired - Lifetime
- 1990-06-07 NZ NZ233972A patent/NZ233972A/en unknown
- 1990-06-07 PT PT94306A patent/PT94306B/pt not_active IP Right Cessation
- 1990-06-07 FI FI902845A patent/FI93219C/fi active IP Right Grant
- 1990-06-08 EP EP90306238A patent/EP0402152B1/fr not_active Expired - Lifetime
- 1990-06-08 ZA ZA904446A patent/ZA904446B/xx unknown
- 1990-06-08 KR KR1019900008394A patent/KR0137455B1/ko not_active Expired - Lifetime
- 1990-06-08 AU AU57019/90A patent/AU625704C/en not_active Expired
- 1990-06-08 NO NO902559A patent/NO177997C/no not_active IP Right Cessation
- 1990-06-08 ES ES90306238T patent/ES2080116T3/es not_active Expired - Lifetime
- 1990-06-08 AT AT90306238T patent/ATE129713T1/de not_active IP Right Cessation
- 1990-06-08 DK DK90306238.8T patent/DK0402152T3/da active
- 1990-06-08 CY CY189490A patent/CY1894A/xx unknown
- 1990-06-08 CH CH90306238T patent/CH0402152H1/fr unknown
- 1990-06-08 IE IE207390A patent/IE69564B1/en not_active IP Right Cessation
- 1990-06-08 DE DE69023280T patent/DE69023280T2/de not_active Expired - Lifetime
- 1990-06-11 JP JP2152494A patent/JPH0662651B2/ja not_active Expired - Lifetime
1994
- 1994-03-04 JP JP6034560A patent/JPH0748391A/ja active Pending
- 1994-05-09 NO NO941726A patent/NO178228C/no not_active IP Right Cessation
1995
- 1995-06-14 HU HU95P/P00204P patent/HU211908A9/hu unknown
- 1995-12-13 GR GR950403512T patent/GR3018379T3/el unknown
1996
- 1996-02-02 LV LVP-96-28A patent/LV11472B/en unknown
- 1996-04-18 HK HK69596A patent/HK69596A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0402152A2 (fr)	1990-12-12
PT94306A (pt)	1991-02-08
CY1894A (en)	1990-06-08
FI902845A0 (fi)	1990-06-07
KR0137455B1 (ko)	1998-05-01
ES2080116T3 (es)	1996-02-01
ATE129713T1 (de)	1995-11-15
AU625704C (en)	2001-07-26
HK69596A (en)	1996-04-26
PT94306B (pt)	1997-05-28
NO941726L (no)	1990-12-10
DK0402152T3 (da)	1995-12-04
AU625704B2 (en)	1992-07-16
FI93219B (fi)	1994-11-30
LV11472B (en)	1996-12-20
FI93219C (fi)	1995-03-10
GR3018379T3 (en)	1996-03-31
ZA904446B (en)	1992-06-24
IE902073L (en)	1990-12-09
AU5701990A (en)	1990-12-13
NZ233972A (en)	1992-05-26
HU211908A9 (en)	1996-01-29
NO902559D0 (no)	1990-06-08
CH0402152H1 (fr)	2006-02-28
KR910000768A (ko)	1991-01-30
NO178228B (no)	1995-11-06
EP0402152A3 (fr)	1991-07-03
NO941726D0 (no)	1994-05-09
NO902559L (no)	1990-12-10
DE69023280T2 (de)	1996-06-20
LV11472A (lv)	1996-08-20
CA2018477C (fr)	1995-08-01
NO177997B (no)	1995-09-25
DE69023280D1 (de)	1995-12-07
NO177997C (no)	1996-01-03
IE69564B1 (en)	1996-10-02
US4922007A (en)	1990-05-01
NO178228C (no)	1996-02-14
CA2018477A1 (fr)	1990-12-09
JPH03101684A (ja)	1991-04-26
JPH0748391A (ja)	1995-02-21
JPH0662651B2 (ja)	1994-08-17
IL94612A0 (en)	1991-04-15
EP0402152B1 (fr)	1995-11-02

Legal Events

Date	Code	Title
1996-09-12	KB	Patent renewed
2000-08-13	NP	Permission for amending the patent specification granted (section 66, patents law 1967)
2004-07-25	KB	Patent renewed
2008-11-03	KB	Patent renewed

Publication	Publication Date	Title
US4922007A (en)	1990-05-01	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en)	1991-05-28	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US4407761A (en)	1983-10-04	Process for the production of ω-amino-1-hydroxyalkylidene-1,1-bisphosphonic acid
CA2169561C (fr)	2007-02-20	Methode de preparation d'acides n-amino-1-hydroxy-alkylidene-1,1-bisphosphoniques
EP0971938B1 (fr)	2002-07-10	Procede de production d'acide 4-amino-1-hydroxybutylidene-1,1-bisphosphonique ou de sels de ce dernier
MXPA02001293A (es)	2002-07-22	Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-disfosfonico y de su sal monosodica trihidratada.
WO2006071128A1 (fr)	2006-07-06	Procede pour la preparation de l’acide [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonique et de son sel monosodique semi-pentahydrate
AU770312B2 (en)	2004-02-19	Novel process for preparing alendronic acid
EP1243592B1 (fr)	2005-06-08	Procédé de préparation de l'acide risédronique
GB2082585A (en)	1982-03-10	6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts.
WO2007010556A1 (fr)	2007-01-25	Procede de production d'acide 4-amino-1-hydroxybutylidene-1,1-bisphosphonique ou sels de celui-ci
CA1146968A (fr)	1983-05-24	Acide 6-amino-1-hydroxyhexylidene- diphosphonique, ses sels et methode pour les preparer
RO112355B1 (ro)	1997-08-29	PROCEDEU IMBUNATATIT DE PREPARARE A ACIDULUI 4-AMII\l0-'l-HIDR0XIBUTILIDEI\M,1-BIF0SF0NIC SAU A SĂRURILOR ACESTUIA